New vector for dyslipidemia treatment: statin dose, not a target cholesterol level (ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults)

Abstract

Ischemic heart disease (CHD) is the main cause of death in more than half of patients with cardiovascular pathology. In 2011, the European Recommendations for the Diagnosis and Correction of Lipid Metabolism Disorders for the Prevention and Treatment of Atherosclerosis were published, and in 2012 - the Russian Recommendations. According to these recommendations, for the successful treatment of patients with high and very high risk, it is necessary to achieve the target level of low density lipoprotein cholesterol (LDL cholesterol), for example, in patients with coronary artery disease less than 1.8 mmol / l. However, despite the modification of the classical risk factors (RF) of atherosclerosis and the conduct of optimal drug therapy in some patients, it is not possible to achieve the target levels of LDL cholesterol and prevent the development of cardiovascular complications (CVC).